However, toxicity issues, variable responses rates and development of resistance due to the activation of other kinases are limiting the efficacy and the clinical progression of these compounds as monotherapy treatment.36 Most recently, work revealing the involvement of KRAS in driving the metabolic phenotype of tumours provides a unique opportunity to search for alternative metabolic approaches to target KRAS mutant tumours.37 Here, KRAS is linked to neoplasm.